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Interleukin  1  (IL-1)  a is  a  15,000-dalton  macrophage-derived protein  that  is 
defined by its ability to induce the differentiation of immature T  lymphocytes 
(1).  In  addition,  recent  work  has  demonstrated  that  IL-1  or  closely  related 
molecules act on the anterior hypothalamus to produce fever (2); act on the liver, 
to induce the production of acute phase proteins such as the  serum  amyloid- 
associated  protein  (SAA)  (3);  and  act  on  synovial  cells to  induce  secretion  of 
prostaglandins and collagenase (4). These diverse properties suggest that IL-1 is 
one of the  major  mediators  of inflammation  in  the  body (5).  Little is  known 
about  the  feedback  regulation  of  the  effects  of  IL-1.  However,  circulating 
antiproteinases such as al-anti-trypsin are thought to be involved in modulating 
inflammatory reactions (6), and  recent reports suggest  that  this  molecule may 
inhibit the in vitro effects of IL-1 as well (7). 
During an investigation of the functional activities of febrile urinary proteins, 
it was noticed that urine from febrile patients contained a potent inhibitor of IL- 
l-induced thymocyte proliferation. In this report, we describe the identification 
and characterization of this inhibitor. 
Methods 
Patients.  Urine was collected from 61  febrile patients,  23 afebrile patients, and  19 
normal volunteers. Febrile patients were classified by their clinical diagnosis and consisted 
of patients with pulmonary or extrapulmonary tuberculosis, other bacterial infections, 
viral infections, or patients with presumed noninfectious etiologies for their fever (i.e., 
acute myocardial infarction, or cerebrovascular accident). 11 ambulatory, febrile patients 
with either viral infections, or localized bacterial infections (i.e., tonsillitis)  but who had 
received no medication of any kind were also studied.  Afebrile patients were selected 
from a  group roughly matched to the  febrile group for age,  sex, and  race, and  had 
diagnoses  of hypertension,  headache,  diabetes,  or  ovarian  cyst.  Patients  with  known 
urinary tract infections or septicemia were excluded from the study. 
Urine Collection and Processing.  Urine was  collected and stored at 4°C.  It was  then 
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dialyzed twice against 100 volumes of phosphate-buffered saline (PBS), pH 7.4, sterilized 
by filtration through a 0.29-/~m Acrodisc filter (Gelman Sciences, Inc., MI) and frozen at 
-70°C until use. 
Mouse Thymocyte Assay.  Before bioassay, all specimens were dialyzed against  100 vol- 
umes of RPMI  1640  (Flow  Laboratories, McLean, VA) and  resterilized by filtration. 
Samples were assayed for IL-I activity with thymocytes from 4-6-wk old C3H/HeJ mice 
(The Jackson Laboratory, Bar Harbor, ME). Single cell suspensions of thymocytes were 
prepared by gently pressing the tissue between the frosted ends of microscope slides. 
Aggregates were removed by a 5-rain unit gravity sedimentation. The cells were washed 
three times with Hanks' Balanced Salt solution (HBSS) and resuspended to a density of 
1.5  x  107  cells/ml  in  RPMI  1640  containing  10%  heat-inactivated fetal calf serum, 
antibiotics, additional 2 mM glutamine, and 2.5 x  10  -s M 2-mercaptoethanol. Thymocytes 
were cultured for 72 h at  1.5  X 106 cells/well in flat-bottom Falcon Microtest III tissue 
culture plates (Becton Dickinson, Oxnard, CA) in the presence or absence of 1 gg/ml 
PHA (purified phytohemagglutinin, Wellcome Research Laboratories, Beckenham, Eng- 
land), IL-1, and various dilutions of test urine. Cultures were pulsed with 0.5 fzCi SH-TdR 
(5.0 Ci/mMol, Amersham Corp., Arlington Heights, IL) for the final 4 h of incubation. 
Cells were collected on glass fiber filter paper using a semiautomated cell harvester (Mash 
II, Microbiological Associates, Bethesda, MD). 
Lymphokines.  Murine IL-1 was obtained from P388D~, cells stimulated with phorbol 
myristic acetate (PMA) (8). The 7-d culture supernatants were centrifuged, concentrated 
by ammonium sulfate precipitation (40-65%  cut), dialyzed twice against  100 volumes 
each of PBS, and frozen in aliquots at -70°C until use. 
Human  IL-1  was  obtained  from  the  culture  supernatant  of endotoxin-stimulated 
peripheral blood mononuclear cells.  This was  partially purified by fast protein liquid 
chromatography (FPLC) and was the generous gift of Dr. Robert Newton (Dupont Corp., 
Wilmington, DE). 
Murine IL-2 was prepared from the supernatant of PMA-stimulated EL-4 ceils using 
the  protocol of Farrar et  al.  (9).  The supernatant  was  centrifuged, concentrated by 
ammonium sulfate precipitation, dialyzed, filtered, and stored as described above. 
Human IL-2 was purified by immuno-affinity chromatography of the culture superna- 
tant of  Jurkatt cells (10) and was the generous gift of Dr. Richard Robb (Dupont Corp.). 
Gel Filtration ofMurine IL-I.  All biochemical manipulations were carried out at 4°C. 
The  supernatant  of PMA-stimulated  P388D,  cells  was  collected and  concentrated as 
described above. 6  ml of the concentrated supernatant was applied to a  2.6- x  74-cm 
Sephacryl S-200 column equilibrated in buffer (50 mM Tris, 100 mM NaC1, pH 7.5). A 
flow rate of 30 ml/h was used and 5-ml fractions were collected. Aliquots of the fractions 
were filter sterilized and assayed for IL-1 activity in the presence or absence of PHA. The 
column was calibrated by marker proteins of known molecular weight. These included 
bovine serum albumin (BSA, tool wt 67,000), ovalbumin (OVA, tool wt 45,000), chymo- 
trypsinogen (CHYMO, tool wt 25,000), and cytochrome C (CYTOC, tool wt 12,400). 
Purification  of Urine Inhibitor.  Urine  from  a  febrile  patient  was  adjusted  to  80% 
saturation with ammonium sulfate by the addition of powdered salt and was kept at 4°C 
overnight. The precipitate was collected by centrifugation at 10,000 rpm for 30 rain, and 
was dissolved in one-tenth of original Volume of buffer (50 mM Tris, 100 mM NaCl, pH 
7.5),  and dialyzed against  the same buffer. The urine concentrate was  applied to the 
Sephacryl S-200 column and chromatographed as described above. 
Quant~cation  oflnterleukins and Urine Inhibitor.  Units of 1L-1 and IL-2 activity were 
determined using the  reciprocal dilution method of Farrar et al.  (I I).  Units of urine 
inhibitor were determined by culturing fourfold dilutions of urine in the presence of 0.25 
U of an IL-I standard. The reciprocal of the highest dilution that produced 30% inhibition 
of IL-1 activity was arbitrarily designated to be the inhibitory units/milliliter of the urine 
sample.  Using  this  system, a  urine  that produced  30%  inhibition only at the highest 
concentration tested (¼ dilution) would be assigned a value of 4 inhibitory units/ml. 128  IDENTIFICATION  OF  A  SPECIFIC  INTERLEUKIN  1  INHIBITOR 
% inhibition  of thymocyte proliferation  was calculated using the formula: 
[ 1- CPM SH-TdR in the presence  of IL-1 +  inhibitor]  % inhibition  CPM SH-TdR in the presence of IL-I  +  mediumJ x  100.  L 
Results 
Identification  of Urine IL-1  Inhibitor.  Because  of the  functional  relationship 
between  IL-1  and endogenous pyrogen, and the small size of this molecule, we 
reasoned that the urine of febrile patients might be a good source of human IL- 
l. Despite numerous attempts, we were unable to detect significant IL-1 activity 
in either whole urine,  or in  urine fractions that were prepared  by a  variety of 
chromatographic  separation  techniques.  However,  during  the  course of these 
experiments  it was noted  that the  febrile  urines were  inhibitory  in  the  mouse 
thymocyte assay. We therefore  investigated the character and specificity of this 
inhibitory effect. 
Febrile urine was repeatedly dialyzed to remove any nonspecific toxic activity 
and filter sterilized. This material was tested for inhibitory activity using a PHA- 
stimulated  mouse  thymocyte  IL-1  assay.  5  U/ml  of  IL-1  produced  a  good 
thymocyte proliferative response (12,500 cpm/cuhure) (Fig.  1). A  1/64 dilution of 
febrile  urine inhibited this response by ~50%  and there was a  dose-dependent 
increase in inhibitory activity. Maximal inhibition was observed at a urine dilution 
of  1A  (95%  inhibition).  In  contrast,  as  seen  in  Fig.  1,  urine  from  a  normal 
individual was much less inhibitory. 
The ability of IL-1  to overcome the effects of the inhibitor (INH) was tested 
next.  A  dilution of urine that contained a known amount of inhibitor (16 INH 
U/ml) was added to culture wells containing increasing amounts of IL-1 (Fig. 2). 
There was an inverse correlation between the amount of IL-1 in culture and the 
degree of inhibition. Inhibition was maximal at suboptimal concentrations of IL- 
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FIGURE  1.  Inhibition of lL-l-induced mouse thymocyte proliferation by febrile urine. Mouse 
thymocytes were  cultured  in  the  presence  of PHA (I  #g/ml),  murine  IL-1  (5 tzg/ml),  and 
increasing  amounts  of  sterile,  dialyzed  urine.  Results  represent  the  arithmetic  means  of 
triplicate cultures. LIAO  ET  AL.  129 
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FIGURE 2.  Competitive antagonism between IL-1 and the urine inhibitor on mouse thymo- 
cyte proliferation. Mouse thymocytes were cultured in the presence of increasing concentra- 
tions of murine IL-I and a fixed amount of sterile, dialyzed febrile urine with known inhibitory 
activity. Results represent the arithmetic means of triplicate cultures. 
1.  Nevertheless,  50%  inhibition  was  still  observed at  a  concentration of IL-1 
(12.5  U/ml) that produced a proliferative response of 50,000 cpm/well. At the 
maximum IL-1  concentration tested (25  U/ml), this dilution of urine was still 
significantly inhibitory (15% inhibition). 
Analysis of the Specificity of the Urine Inhibitor.  We next sought to determine the 
specificity of the urine inhibitor. Recent reports suggested that phorbol myristate 
acetate (PMA) may contaminate IL-1  preparations and be a significant mitogen 
in some in vitro assays (12). We therefore subjected the crude IL-1  preparation 
to further purification by Sephacryl S-200 gel filtration. This procedure has been 
shown to separate IL-1 from contaminating PMA (13). Two peaks were mitogenic 
for thymocytes in the presence of PHA (Fig. 3). One was ~ 15,000 daltons, which 
corresponded to the  molecular weight of IL-1,  and  the second was >50,000 
daltons, which corresponded to the presumptive elution profile of PMA bound 
to protein  (13).  PMA does not stimulate thymocytes in  the absence of PHA, 
while  IL-1  exhibits a  diminished but  significant thymocyte mitogenic activity 
(12). We therefore retested the column fractions in the absence of PHA. Under 
these conditions, only the  15  peak  was mitogenic for thymocytes, confirming 
that it contained the authentic IL-1. 
The urine inhibitor was then tested for activity against this partially purified 
IL-1  preparation.  It  was  found  to  be  as  active  against  the  15-kdalton  peak 
material as it was against the less pure preparation (Fig.  4),  indicating that the 
inhibitor was blocking the effects of IL-1 and not the contaminating PMA. 
Several other aspects of this experiment suggested that the inhibitor was acting 
against  IL-1.  First,  the inhibitor  blocked the mitogenic effects of IL-1  in  the 
absence of PHA. Secondly, it was not inhibitory in the absence of IL-1, so that 
neither the low level spontaneous proliferative activity of thymocytes nor the 
small  amount  of proliferation  induced  by  PHA  alone  was  effected  by  the 130  IDENTIFICATION  OF  A  SPECIFIC  INTERLEUKIN  1  INHIBITOR 
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FmURE  3.  Fractionation  of  crude  murine  IL-1  by  molecular  sieve  chromatography  on 
Sephacryi S-200. The culture supernatant of PMA-stimulated P388DI, cells was concentrated 
and applied  to the column as outlined in the methods section.  Fractions of column effluent 
were tested for murine thymocyte  mitogenic activity in the presence or absence of PHA (1 
/zg/ml). K, kilodaltons. 
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FIGURE 4.  Comparative effect of the urine inhibitor on thymocyte proliferation in response 
to crude  or partially purified IL-1.  The  proliferative response of murine  thym~cytes under 
each of the specified conditions was tested in the presence of increasing amounts of sterile, 
dialyzed  febrile  urine.  Results  represent  the  arithmetic  means  of triplicate  cultures.  The 
thymocyte proliferation (cpm/culture) in response to the various stimulants were: murine IL- 
l  15K Peak (+  PHA) =  26,132/culture;  murine  IL-1  (No  PHA) --  18,229/culture;  murine 
IL-I (+ PHA) =  24,473[culture;  PHA alone =  1,224/culture; no stimulant =  542/culture. 
inhibitor.  Taken  together  these  experiments  suggest  that  the  inhibitor  was 
specific for IL-1, and was not blocking the effects of PHA, nor was it nonspecif- 
ically toxic for thymocytes. 
We next investigated  the effects of inhibitor on another thymocyte mitogen, LIAO  ET  AL.  131 
interleukin-2  (IL-2).  For  these  studies  we  analyzed  the  effects  of  the  urine 
inhibitor  against  four  preparations:  human  and  mouse  IL-1,  and  human  and 
mouse IL-2. A fixed amount of urine inhibitor (16 U/ml) had no effect at all on 
IL-2-induced  thymocyte  proliferation  (Fig.  5).  Increasing  concentrations  of 
inhibitor were also tested against a fixed amount of IL-2 in separate experiments, 
but again up to 128 U/ml of inhibitor had no effect on IL-2-induced  thymocyte 
proliferation (data not shown).  The inhibitor was also tested against human  IL- 
l, and was found to be more active against this material than against murine IL- 
l  (Fig. 5). These findings confirm that the urine inhibitor is specific for IL-1. 
Characterization  of the Urine Inhibitor.  A  preliminary  physicochemical  charac- 
terization of the urine inhibitor was performed next. Urine was concentrated by 
ammonium sulfate fractionation, and subjected to Sephacryi S-200 gel filtration. 
The inhibitor eluted from the gel in a moderately narrow and symmetrical peak 
with an apparent  molecular  weight of 20-40  kdaltons  (Fig.  6),  consistent  with 
the behavior of a low molecular weight urine protein. 
Patient Studies.  Urine samples were next collected from a number of normal 
individuals, afebrile patients, and from patients with fevers of diverse etiologies, 
and tested for IL-1  inhibitor activity. 
Normal individuals had low levels of activity, ranging from 0-100  U/ml, with 
a mean of 36  U/ml  (Fig.  7). The activity in afebrile patients was similar to that 
of controls (mean =  27 U/ml). Febrile patients were subdivided into five groups. 
The mean urine inhibitory activity in all febrile patients was significantly greater 
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FIGURE  .5.  Comparative effect  of the urine inhibitor on  IL-1  and  IL-2  induced thymocyte 
proliferation.  Increasing concentrations of interleukin were tested in presence or absence of a 
fixed amount (16  U/ml) of sterile dialyzed febrile urine. The  interleukins were prepared as 
described in the methods section. Results represent the arithmetic means of triplicate cultures. 
Thymocyte proliferation (cpm/cuhure) in response to these interleukins fell into the following 
ranges (1/12sJ,4 dilutions): human IL-1  8,229-36,620;  mouse IL-1  12,640-44,820;  human IL- 
2  44.300-152,200;  mouse IL-2 26.684-112,400. 132  IDENTIFICATION  OF  A  SPECIFIC  INTERLEUKIN  1  INHIBITOR 
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FIGURE 6.  Fractionation  of the  urine  inhibitor  by  molecular  sieve  chromatography  on 
Sephacryl S-200. Febrile urine was concentrated (10-fold) by ammonium sulfate precipitation, 
dialyzed  and  6  ml  was  applied  to  the  column.  Column  effluent  fractions  were  dialyzed, 
sterilized, and tested for inhibitory activity in the presence of murine IL-1 (2.5 U/ml). Results 
represent the arithmetic means of triplicate cultures. Thymocyte proliferation in response to 
IL-1 (+ PHA) =  27,650 cpm/culture. 
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FIGURE 7.  Quantification  of inhibitor concentrations  in  the  urine of normal  and  febrile 
individuals. Urine from each of the patients was dialyzed, sterilized, and tested for inhibitory 
activity in the presence of murine IL-1 (2.5 U/ml). The inhibitory activity of each sample was 
calculated using the formula described in the methods section. LIAO  ET  AL.  133 
than that of the afebrile individuals. The highest activities were found in patients 
with bacterial infections or tuberculosis, and every patient in this group had an 
elevated urine inhibitor titer.  Inhibitor titers in patients with viral infections or 
noninfectious fevers were also  elevated,  but  in  these  groups,  titers  of some 
patients fell into the normal range. 
Because of the possibility that the urine inhibitory activity was due to protein- 
bound urinary drug metabolites, a  large group of ambulatory, febrile patients 
were carefully screened for drug usage.  11  patients were found that had not 
taken any medication including antipyretics or antibiotics for at least 24 h before 
urine collection. Inhibitor levels in this group ranged from 38-340 #g/ml with 
a mean of 151 #g/ml. 
These  findings  indicate  that  the  IL-1  inhibitor  is  a  normal  constituent of 
human urine but that the urine levels of this material are significantly increased 
in febrile states. 
Discussion 
We have found that the urine of febrile patients contains a potent inhibitor of 
IL-l-induced thymocyte proliferation.  Our  data  suggest  that  this  material  is 
specific for IL-1 and is not a nonspecific immuno-suppressive molecule, since the 
inhibitor has relatively little effect of spontaneous or PHA-induced thymocyte 
proliferation. More importantly, it does not inhibit the proliferative effects of 
another thymocyte mitogen, interleukin 2.  Our findings also indicate that this 
inhibitor is present in small amounts in the urine of normal individuals, but is 
increased during febrile states of many etiologies. 
The nature of this inhibitor remains to be determined. Gel filtration analysis 
indicates that it is a molecule of 20-40 kdaltons. Preliminary analysis on a two- 
dimensional gel suggests that it is a  protein or glycoprotein (data not shown). 
However, definitive identification will require additional purification and analy- 
sis. Nevertheless, there is evidence suggesting that the urine inhibitor may be a 
protease inhibitor and/or a  liver-derived acute phase protein. In addition to its 
relationship to  endogenous pyrogen and  fever (14),  IL-1  has been  shown  to 
stimulate hepatic synthesis of several acute phase proteins including the SAA 
protein (3) and C-reactive protein (CRP) (15).  It is also known that  SAA will 
inhibit T  cell mitogenesis in vitro (16). Although the urine inhibitor is too small 
to be either of these molecules, it is possible that it is either a proteolytic fragment 
or a subunit of SAA, CRP, or another immunosuppressive acute phase protein 
such as a2-macroglobulin (17). 
Another possibility  is  that  the  urine inhibitor  is  related to  al-antiprotease, 
which is also an acute phase reactant (5).  This serum protease inhibitor blocks 
PHA-induced T  cell proliferation in vitro (18) and has been recently found to 
block the effect of IL-1 on thymocytes in vitro (7).  Again, the urine inhibitor is 
too small to be intact oq-antiprotease, but could be a fragment of this molecule. 
It is noteworthy that both  a~-antiprotease as well as other protease inhibitors 
have been found in human urine (19). It is also interesting that fragments of the 
inter aa trypsin inhibitor have been identified in urine, and that these fragments 
fall within the same molecular weight range as the urine IL-1  inhibitor (20-40 
kdaltons) (20). 134  IDENTIFICATION  OF  A  SPECIFIC  INTERLEUKIN  1  INHIBITOR 
A  number of other inhibitors  of T  cell proliferation  have been identified in 
humans,  but their relationship to the urine IL-1  inhibitor is not clear. Morse et 
al.  (21),  described  a  20-40-kdalton  inhibitor  that  is  present  in  the  urine  of 
pregnant women. This inhibitor acts on peripheral T  cells, and has not yet been 
tested for interleukin-blocking activity. Dinarello et al., (22) identified an inhib- 
itor of IL-1 in the serum of endotoxin-treated human volunteers, that was bound 
by a  polyclonal  anti-IL-1  antibody.  It  is  not  clear  whether  this  observation 
indicates that the serum inhibitor is antigenically related to I L-1, if the polyclonal 
antibody  is  not  monospecific,  or if the  inhibitor  is  bound  to  circulating  IL-1. 
Other  T  cell-suppressive  factors  have  also  been  identified  in  human  serum. 
Kleinhenz  et al.  (23) have suggested that  an  immunosuppressive  factor in  the 
plasma  of patients  with  miliary  tuberculosis  is  mycobacterial  arabinogalactan 
(23). However, the physicochemical nature of the urine IL-1 inhibitor described 
in  this  report  as  well  as  its  presence  in  a  number  of nonmycobacterial  and 
noninfectious febrile states suggest that it is not related to arabinogalactan. 
Recently, Amento et al.  (24) have identified an inhibitor  of IL-l-induced  T 
cell activation that is produced by the human  macrophage cell line,  U937 (24). 
This material had an apparent molecular weight of 45-60 kdaltons. The similar- 
ity between this molecule and the urine inhibitor has not yet been investigated. 
However,  these  findings  raise  the  interesting  possibility  that  the  urine  IL-1 
inhibitor may be a macrophage product. 
It is reasonable to assume that the urine IL-1 inhibitor is a part of a physiolog- 
ical feedback mechanism.  An inflammatory stimulus would induce macrophage 
production  of IL-I,  which  in  turn  would produce fever and  stimulate  hepatic 
synthesis of acute phase proteins. One or more of these proteins or a macrophage- 
derived  inhibitor  could  then  act  as  suppressors  of IL-1  and  damp-down  the 
inflammatory response. Presumably the urine inhibitor is derived from some low 
molecular weight (<50 kdaltons) serum IL-1  inhibitory protein that is excreted 
into the urine or is a fragment of some larger serum protein. 
One  problem  with  this  interpretation,  is  that  the  increased  levels  of urine 
inhibitor  seen  in  febrile  states  may  not  reflect  an  increased  synthesis  of this 
molecule, but may be the result of the general increased concentration of urine 
proteins that occurs with fever (25). It is less likely that the inhibitor is a protein- 
bound urinary drug metabolite or a microbial product, since urines from presum- 
ably  drug-free  febrile  individuals,  and  from  febrile  patients  without  known 
infections also contained significant levels of the IL-1  inhibitor.  A more precise 
identification of the urine IL-1 inhibitor and the ability to measure this molecule 
in serum should enable us to answer these questions, as well as to clarify the role 
of the  urine  inhibitor  in  the  physiological regulation  of IL-l-induced  inflam- 
mation. 
Summary 
The urine of febrile patients has been found to contain high concentrations of 
an inhibitor of interleukin  1 (IL-1)-induced thymocyte proliferation. The inhib- 
itor is specific for IL-1  and does not block the effects of interleukin  2 (IL-2) or 
phytohemagglutin  (PHA) on thymocytes, and it is not nonspecifically toxic for 
these cells.  IL-I  inhibitor  can be found in the urine of normal  individuals and LIAO  ET  AL.  135 
afebrile patients, but is present in increased concentrations in the urine of patients 
with  fever  of diverse  etiologies.  Preliminary physicochemical characterization 
indicates that the inhibitor is a  20-40-kdalton protein. 
The authors would like to express their appreciation to Betty Donovan for her help in 
preparation of the manuscript. 
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